New Anti-Foot-and-Mouth Disease Vaccine Advances in Argentina
- Researchers are developing a novel vaccine against Aphid fever virus using non-infective material during the production and distribution process.
- Researchers at the national Institute of agricultural Technology (INTA), along with collaborators from Canada's NRCC and the private company Bioinnovo, are developing a first-of-its-kind vaccine against Aphid fever...
- According to a researcher, the existing vaccine against Aphid fever, while effective, has room for improvement.
New Vaccine Against Aphid Fever Virus Under Advancement
Table of Contents
- New Vaccine Against Aphid Fever Virus Under Advancement
- New Vaccine Against aphid Fever Virus: A Q&A
- what is the new vaccine for Aphid fever virus and how is it different?
- Who is developing this new vaccine?
- Why is a new vaccine needed?
- How is the new vaccine produced?
- What are the potential benefits of this new vaccine?
- How does this new vaccine compare to the previous vaccine?
- who made the previous vaccine?
Researchers are developing a novel vaccine against Aphid fever virus using non-infective material during the production and distribution process.
Researchers at the national Institute of agricultural Technology (INTA), along with collaborators from Canada’s NRCC and the private company Bioinnovo, are developing a first-of-its-kind vaccine against Aphid fever virus. The key innovation is that the vaccine is produced without using any infective material.
According to a researcher, the existing vaccine against Aphid fever, while effective, has room for improvement. A meaningful challenge is the need for a type-3 safety plant, a high-security laboratory, to prevent the virus from escaping.
The new vaccine is produced in mammalian cells without using infective material at any stage. Specialists believe this approach is safer and more effective, and it can be implemented in existing plants without increasing internal security levels.
The researcher explained the process: What we did was searching the genes,that is,the DNA sequences,which manufacture the four proteins that generate the virus capsule and put them into a mammalian cell in collaboration with the NRCC of Canada,and we develop a line that,in its genome,retains those four proteins and we put together a false virus. Before a microscope is the same, but on the outside they are empty, although for the immune system they are virus, but with an empty box.
this innovation could substantially reduce production costs. Thus, how to have a plant (laboratory), it is indeed very expensive, if you could have a vaccine that has the same qualities but that no longer requires that plant would imply a tremendous improvement.
The researcher added, What we did was develop a vaccine that is manufactured using the same infrastructure, that is, using the tachys where cells and system grow how the virus is purified, but that does not handle infectious material.
The vaccine has been successfully tested in laboratory mice, cattle, and pigs. In all cases we had antibody titles equal to those obtained with the conventional oily vaccine,
the researcher stated.
The researcher also acknowledged the work of Scholeim Rivenson, who created the oily vaccine against Aphid fever. Rivenson’s work led to the eradication of Aphid fever in Argentina after 120 years. He was also the creator and director of the veterinary Science Research Center.
New Vaccine Against aphid Fever Virus: A Q&A
what is the new vaccine for Aphid fever virus and how is it different?
Researchers are developing a novel vaccine against Aphid fever virus, marking a significant advancement in veterinary medicine. The key innovation of this new vaccine is that it’s produced without using any infectious material. This is a first-of-its-kind approach that could revolutionize how this disease is combatted.
Who is developing this new vaccine?
The vaccine is being developed by researchers at the National Institute of Agricultural Technology (INTA), in collaboration with Canada’s NRCC and the private company Bioinnovo.
Why is a new vaccine needed?
While existing vaccines against Aphid fever are effective,they have limitations. One significant challenge is the need for a high-security laboratory (type-3 safety plant) to prevent the virus from escaping. The new vaccine aims to overcome this challenge by being produced in a safer manner.
How is the new vaccine produced?
The new vaccine is produced in mammalian cells without using infectious material at any stage. This safer approach can be implemented in existing plants without increasing internal security levels.
Here’s a breakdown of the production process:
The researchers identified the genes, or DNA sequences, that create the four proteins forming the virus capsule.
these genes are inserted into mammalian cells.
A cell line is developed that contains these four proteins.
This process creates a “false virus” that,although appearing identical to the actual virus under a microscope,is empty and non-infectious.
The immune system recognizes it and reacts as if it were the real virus.
What are the potential benefits of this new vaccine?
The new vaccine may provide several advantages:
Enhanced Safety: The production method eliminates the need for high-security laboratories,thus minimizing the risk of virus escape.
Cost Reduction: Eliminating the need for a type-3 safety plant could significantly reduce production costs.
Compatibility: The vaccine can be manufactured using existing infrastructure.
* Effectiveness: Laboratory tests on mice, cattle, and pigs have shown that the new vaccine generates antibody levels equivalent to those provided by conventional, existing vaccines.
How does this new vaccine compare to the previous vaccine?
Here’s a comparison of the new vaccine against Aphid fever virus with the previous one:
| Feature | New Vaccine | Previous Vaccine |
| :————– | :———————————————————————– | :———————————————– |
| Production Material | No infectious material | Infectious material |
| Safety Requirements | Lower (existing plants can be used) | High (requires a type-3 safety plant) |
| Production Costs | Potentially lower | can Be High |
| Antibody Response | Equivalent to previous vaccine | Effective |
who made the previous vaccine?
The previous vaccine was developed by scholeim rivenson, whose work led to the eradication of Aphid fever in argentina after 120 years. He was also the creator and director of the Veterinary Science Research Center.